Chemoinformaics analysis of toxyloxanthone B
Molecular Weight | 326.304 | nRot | 0 |
Heavy Atom Molecular Weight | 312.192 | nRig | 22 |
Exact Molecular Weight | 326.079 | nRing | 4 |
Solubility: LogS | -3.855 | nHRing | 2 |
Solubility: LogP | 3.909 | No. of Aliphatic Rings | 1 |
Acid Count | 0 | No. of Aromatic Rings | 3 |
Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
Atoms Count | 38 | No. of Aliphatic Hetero Cycles | 1 |
No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 2 |
nHetero | 6 | No. of Aromatic Hetero Cycles | 1 |
nBridge Head | 0 | No. Saturated Carbocycles | 0 |
No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 0 |
No. of Carbon atom | 18 | No. of Saturated Rings | 0 |
No. of Nitrogen atom | 0 | No. of Arom Atom | 14 |
No. of Oxygen atom | 6 | No. of Arom Bond | 16 |
nHA | 6 | APOL | 44.2071 |
nHD | 3 | BPOL | 18.3849 |
QED | 0.548 |
Synth | 3.114 |
Natural Product Likeliness | 2.526 |
NR-PPAR-gamma | 0.974 |
Lipinski | Accepted |
Pfizer | Accepted |
GSK | Accepted |
Golden Triangle | Accepted |
Pgp-inh | 0.005 |
Pgp-sub | 0.007 |
HIA | 0.08 |
CACO-2 | -4.902 |
MDCK | 0.0000149 |
BBB | 0.007 |
PPB | 0.97037 |
VDSS | 0.616 |
FU | 0.0689807 |
CYP1A2-inh | 0.957 |
CYP1A2-sub | 0.512 |
CYP2c19-inh | 0.185 |
CYP2c19-sub | 0.058 |
CYP2c9-inh | 0.77 |
CYP2c9-sub | 0.931 |
CYP2d6-inh | 0.685 |
CYP2d6-sub | 0.267 |
CYP3a4-inh | 0.402 |
CYP3a4-sub | 0.091 |
CL | 3.01 |
T12 | 0.665 |
hERG | 0.018 |
Ames | 0.416 |
ROA | 0.234 |
SkinSen | 0.736 |
Carcinogencity | 0.482 |
EI | 0.895 |
Respiratory | 0.375 |
NR-Aromatase | 0.86 |
Antiviral | Yes |
Prediction | 0.65345 |